Current Status and Growth of Nuclear Theranostics in Singapore
10.1007/s13139-019-00580-3
- Author:
Hian Liang HUANG
1
;
Aaron Kian Ti TONG
;
Sue Ping THANG
;
Sean Xuexian YAN
;
Winnie Wing Chuen LAM
;
Kelvin Siu Hoong LOKE
;
Charlene Yu Lin TANG
;
Lenith Tai Jit CHENG
;
Gideon Su Kai OOI
;
Han Chung LOW
;
Butch Maulion MAGSOMBOL
;
Wei Ying THAM
;
Charles Xian Yang GOH
;
Colin Jingxian TAN
;
Yiu Ming KHOR
;
Sumbul ZAHEER
;
Pushan BHARADWAJ
;
Wanying XIE
;
David Chee Eng NG
Author Information
1. Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, 1 Outram Road, Singapore 169608, Singapore. huang.hian.liang@singhealth.com.sg
- Publication Type:Brief Communication
- From:Korean Journal of Nuclear Medicine
2019;53(2):96-101
- CountryRepublic of Korea
- Language:English
-
Abstract:
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
